Coya Financial Statements From 2010 to 2025

COYA Stock   6.08  0.22  3.75%   
Coya Therapeutics, financial statements provide useful quarterly and yearly information to potential Coya Therapeutics, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Coya Therapeutics, financial statements helps investors assess Coya Therapeutics,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Coya Therapeutics,'s valuation are summarized below:
Gross Profit
-2 M
Profit Margin
(1.12)
Market Capitalization
97.9 M
Enterprise Value Revenue
11.9036
Revenue
9.6 M
We have found one hundred one available fundamental signals for Coya Therapeutics, Common, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Coya Therapeutics, Common prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of February 1, 2025, Market Cap is expected to decline to about 42.2 M. In addition to that, Enterprise Value is expected to decline to about 34.5 M

Coya Therapeutics, Total Revenue

7.25 Million

Check Coya Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coya Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.4 K, Interest Expense of 2.9 M or Selling General Administrative of 9.5 M, as well as many indicators such as Price To Sales Ratio of 10.04, Dividend Yield of 0.0 or PTB Ratio of 3.84. Coya financial statements analysis is a perfect complement when working with Coya Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Coya Therapeutics, Correlation against competitors.

Coya Therapeutics, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets49.8 M47.5 M15.5 M
Slightly volatile
Total Current Liabilities6.1 M5.8 M1.7 M
Slightly volatile
Accounts Payable1.2 M1.3 M703.2 K
Slightly volatile
Cash39.4 M37.5 M13.5 M
Slightly volatile
Cash And Short Term Investments39.4 M37.5 M13.5 M
Slightly volatile
Net Receivables9.1 M8.6 M2.5 M
Slightly volatile
Common Stock Shares Outstanding10.9 M11.7 M9.9 M
Slightly volatile
Liabilities And Stockholders Equity49.8 M47.5 M15.5 M
Slightly volatile
Non Current Liabilities Total627.8 K660.9 K1.3 M
Pretty Stable
Other Current Assets1.1 M1.2 M400.2 K
Slightly volatile
Other Stockholder Equity74.3 M70.7 M13.1 M
Slightly volatile
Total Liabilities6.6 M6.5 M2.6 M
Slightly volatile
Total Current Assets49.7 M47.4 M15.4 M
Slightly volatile
Capital Stock1.2 K1.3 K7.1 M
Slightly volatile
Net Working Capital43.6 M41.6 M13.7 M
Slightly volatile
Common Stock1.7 K1.7 K513
Slightly volatile
Non Currrent Assets Other662.5 K1.3 M326.8 K
Slightly volatile
Other Assets662.5 K1.3 M326.8 K
Slightly volatile
Deferred Long Term Liabilities662.5 K1.3 M326.8 K
Slightly volatile
Property Plant Equipment85.6 K84 K112.8 K
Slightly volatile
Short and Long Term Debt Total10.4 M11.7 M12.7 M
Slightly volatile
Long Term Debt10.4 M11.7 M12.7 M
Slightly volatile
Current Deferred Revenue738.5 K830.8 K905.8 K
Slightly volatile
Short Term Debt579.1 K651.5 K710.3 K
Slightly volatile

Coya Therapeutics, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization23.4 K24.6 K491.9 K
Slightly volatile
Interest Expense2.9 M2.8 M690.7 K
Slightly volatile
Selling General Administrative9.5 MM2.6 M
Slightly volatile
Selling And Marketing Expenses356.1 K400.6 K436.8 K
Slightly volatile
Other Operating Expenses8.1 M16 M3.8 M
Slightly volatile
Research Development3.8 MM1.7 M
Slightly volatile
Total Operating Expenses8.1 M16 M3.8 M
Slightly volatile
Cost Of Revenue26 K31.5 K19.1 K
Slightly volatile
Reconciled Depreciation26 K31.5 K19.1 K
Slightly volatile

Coya Therapeutics, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings7.8 M12 M3.4 M
Slightly volatile
Depreciation23.9 K31.5 K19 K
Slightly volatile
End Period Cash Flow39.4 M37.5 M13.5 M
Slightly volatile
Change To Netincome3.9 M3.7 M1.2 M
Slightly volatile
Change To Liabilities611.7 K972.1 K354.7 K
Slightly volatile
Stock Based Compensation1.1 MM370.9 K
Slightly volatile
Begin Period Cash Flow5.1 M5.3 M7.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.0411.2912.3124
Slightly volatile
Days Sales Outstanding365410448
Slightly volatile
Average Payables1.1 M1.2 M1.3 M
Slightly volatile
Stock Based Compensation To Revenue0.120.130.1428
Slightly volatile
Capex To Depreciation6.787.638.3204
Slightly volatile
EV To Sales5.696.46.9786
Slightly volatile
Payables Turnover0.01540.02130.0188
Very volatile
Sales General And Administrative To Revenue1.051.171.2807
Slightly volatile
Research And Ddevelopement To Revenue0.810.910.9887
Slightly volatile
Cash Per Share3.032.891.2553
Slightly volatile
Days Payables Outstanding21.6 K17.7 K19.5 K
Very volatile
Income Quality0.661.260.6612
Slightly volatile
Current Ratio9.249.3815.4931
Slightly volatile
Receivables Turnover0.640.720.7853
Slightly volatile
Graham Number7.447.092.6913
Slightly volatile
Capex Per Share0.01130.01270.0139
Slightly volatile
Revenue Per Share0.470.530.5792
Slightly volatile
Interest Debt Per Share1.461.390.4711
Slightly volatile
Debt To Assets1.231.391.515
Slightly volatile
Operating Cycle365410448
Slightly volatile
Days Of Payables Outstanding21.6 K17.7 K19.5 K
Very volatile
Ebt Per Ebit1.171.061.0631
Pretty Stable
Long Term Debt To Capitalization2.272.552.7826
Slightly volatile
Total Debt To Capitalization2.272.552.7826
Slightly volatile
Quick Ratio9.249.3815.4931
Slightly volatile
Net Income Per E B T0.880.991.0072
Pretty Stable
Cash Ratio8.67.4315.148
Slightly volatile
Days Of Sales Outstanding365410448
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.830.931.0157
Slightly volatile
Fixed Asset Turnover72.8181.9189.3062
Slightly volatile
Debt Ratio1.231.391.515
Slightly volatile
Price Sales Ratio10.0411.2912.3124
Slightly volatile
Asset Turnover0.120.130.1429
Slightly volatile
Gross Profit Margin0.80.90.9773
Slightly volatile

Coya Therapeutics, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap42.2 M67.8 M47.7 M
Slightly volatile
Enterprise Value34.5 M38.4 M37.5 M
Slightly volatile

Coya Fundamental Market Drivers

Cash And Short Term Investments32.6 M

Coya Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Coya Therapeutics, Financial Statements

Coya Therapeutics, stakeholders use historical fundamental indicators, such as Coya Therapeutics,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although Coya Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Coya Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Coya Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Coya Therapeutics, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue830.8 K738.5 K
Total Revenue6.9 M7.2 M
Cost Of Revenue31.5 K26 K
Stock Based Compensation To Revenue 0.13  0.12 
Sales General And Administrative To Revenue 1.17  1.05 
Research And Ddevelopement To Revenue 0.91  0.81 
Revenue Per Share 0.53  0.47 
Ebit Per Revenue(1.19)(1.24)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Coya Therapeutics, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics, Common Stock:
Check out the analysis of Coya Therapeutics, Correlation against competitors.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.65)
Revenue Per Share
0.687
Return On Assets
(0.29)
Return On Equity
(0.51)
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.